Skip to main content
SpringerLink
Log in

Hepatocellular carcinoma: Therapeutic strategy in 2017

Carcinome hépatocellulaire: stratégie thérapeutique en 2017

  • Update / Mise au Point
  • Published:
Oncologie

Abstract

Hepatocellular carcinoma (HCC) is the most frequent primary neoplasm of the liver and it is the most relevant cause of death among patients with chronic liver disease. Prognosis assessment is a critical step in the management of HCC patients. Any attempt to assess the prognosis should consider not only information regarding tumor stage but also data about the degree of liver function impairment and the presence of cancer-related symptoms. In addition, any system aimed to be clinically successful should optimally attempt to link prognostic prediction and treatment indication. The Barcelona Clinic Liver Cancer staging system is the most accepted staging system. It has been externally validated, takes into account the most relevant prognostic parameters, and suggests the treatment approach based on the best scientific evidence. This article summarizes the most updated treatment strategy of HCC and future perspectives.

Résumé

Le carcinome hépatocellulaire (CHC) est la néoplasie hépatique primitive la plus fréquente et constitue la principale cause de décès chez les patients souffrant d’une maladie chronique du foie. L’évaluation du pronostic est une étape essentielle à la prise en charge des patients souffrant de CHC. Toute tentative d’évaluation du pronostic doit prendre en compte non seulement le stade de la tumeur, mais également les données quant au degré d’atteinte de la fonction hépatique et à la présence de symptômes associés au cancer. De plus, tout système visant un succès clinique doit essayer, de manière optimale, d’associer pronostic et indication de traitement. La classification de la clinique pour le cancer du foie de Barcelone (Barcelona Clinic Liver Cancer [BCLC]) est le système de classification le plus largement accepté. Elle a fait l’objet d’une validation externe, prend en compte les paramètres pronostiques les plus pertinents et propose l’approche thérapeutique fondée sur les meilleures données scientifiques.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Références

  1. Ferlay J, Soerjomataram I, Dikshit R, et al (2015) Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E86

    Article  CAS  PubMed  Google Scholar 

  2. Forner A, Díaz-González A, Liccioni A, et al (2014) Prognosis prediction and staging. Best Pract Res Clin Gastroenterol 28:855–65

    Article  PubMed  Google Scholar 

  3. Bruix J, Reig M, Sherman M (2016) Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150:835–53

    Article  PubMed  Google Scholar 

  4. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–38

    Article  CAS  PubMed  Google Scholar 

  5. Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379:1245–55

    Article  PubMed  Google Scholar 

  6. Cho YK, Kim JK, Kim WT, et al (2010) Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology 51:1284–90

    Article  PubMed  Google Scholar 

  7. Berzigotti A, Reig M, Abraldes JG, et al (2015) Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology 61:526–36

    Article  PubMed  Google Scholar 

  8. Ishizawa T, Hasegawa K, Aoki T, et al (2008) Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 134:1908–16

    Article  PubMed  Google Scholar 

  9. Mazzaferro V (2016) Squaring the circle of selection and allocation in liver transplantation for HCC: an adaptive approach. Hepatology 63:1707–17

    Article  PubMed  PubMed Central  Google Scholar 

  10. Bruix J, Han KH, Gores G, et al (2015) Liver cancer: approaching a personalized care. J Hepatol 62:S144–S56

    Article  PubMed  PubMed Central  Google Scholar 

  11. Bruix J, Takayama T, Mazzaferro V, et al (2015) Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebocontrolled trial. Lancet Oncol 16:1344–54

    Article  CAS  PubMed  Google Scholar 

  12. Llovet JM, Real MI, Montana X, et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–9

    Article  PubMed  Google Scholar 

  13. Lo CM, Ngan H, Tso WK, et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–71

    Article  CAS  PubMed  Google Scholar 

  14. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–42

    Article  CAS  PubMed  Google Scholar 

  15. EASL-EORTC Clinical Practice Guidelines (2012) Management of hepatocellular carcinoma. J Hepatol 56:908–43

    Article  Google Scholar 

  16. Forner A, Gilabert M, Bruix J, et al (2014) Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol 11:525–35

    Article  CAS  PubMed  Google Scholar 

  17. Lammer J, Malagari K, Vogl T, et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Interv Radiol 33:41–52

    Article  Google Scholar 

  18. Golfieri R, Giampalma E, Renzulli M, et al (2014) Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 111:255–64

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Burrel M, Reig M, Forner A, et al (2012) Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol 56:1330–5

    PubMed  Google Scholar 

  20. Malagari K, Pomoni M, Moschouris H, et al (2012) Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Interv Radiol 35:1119–28

    Article  Google Scholar 

  21. Takayasu K, Arii S, Kudo M, et al (2012) Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol 56:886–92

    Article  PubMed  Google Scholar 

  22. Bruix J, Reig M, Rimola J, et al (2011) Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology 54: 2238–44

    Article  PubMed  Google Scholar 

  23. Lencioni R, Llovet JM, Han G, et al (2016) Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol 64:1090–8

    Article  CAS  PubMed  Google Scholar 

  24. Kudo M, Han G, Finn RS, et al (2014) Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology 60:1697–707

    Article  CAS  PubMed  Google Scholar 

  25. Llovet JM, Ricci S, Mazzaferro V, et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–90

    Article  CAS  PubMed  Google Scholar 

  26. Cheng AL, Kang YK, Chen Z, et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34

    Article  CAS  PubMed  Google Scholar 

  27. Reig M, Torres F, Rodriguez-Lope C, et al (2014) Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol 61: 318–24

    Article  CAS  PubMed  Google Scholar 

  28. Bruix J, Qin S, Merle P, et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet 389:56–66

    Article  CAS  PubMed  Google Scholar 

  29. Sangro B (2014) Chemoembolization and radioembolization. Best Pract Res Clin Gastroenterol 28:909–19

    Article  CAS  PubMed  Google Scholar 

  30. Ribeiro de Souza A, Reig M, Bruix J (2016) Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. Expert Opin Pharmacother 17:1923–36

    Article  CAS  PubMed  Google Scholar 

  31. El-Khoueiry AB, Sangro B, Yau T, et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet-pii: S0140-6736(17)31046-2. doi: 10.1016/S0140-6736(17)31046-2

    Google Scholar 

  32. Santoro A, Rimassa L, Borbath I, et al (2013) Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 14:55–63

    Article  CAS  PubMed  Google Scholar 

  33. Zhu AX, Park JO, Ryoo BY, et al (2015) Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 16:859–70

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Barcelona Clinic Liver Cancer (BCLC) group, Liver Unit, CIBEREHD, IDIBAPS Hospital Clinic c/ Villarroel, 170, Escala 11, 4a planta, 08036, Barcelona, Spain

    A. Díaz-González & A. Forner

  2. Centro de Investigación Biomédica en Red, de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain

    A. Díaz-González & A. Forner

Authors
  1. A. Díaz-González
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Forner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Forner.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Díaz-González, A., Forner, A. Hepatocellular carcinoma: Therapeutic strategy in 2017. Oncologie 19, 177–183 (2017). https://doi.org/10.1007/s10269-017-2713-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-017-2713-1

Keywords

Mots clés

Search

Navigation